1. Pharmaceutical firms also conduct research to assess the efficiency of a treatment program. Suppose a new anti-viral drug for COVID-19 is currently under investigation, this is given to patients...

Extracted text: 1. Pharmaceutical firms also conduct research to assess the efficiency of a treatment program. Suppose a new anti-viral drug for COVID-19 is currently under investigation, this is given to patients after the signs of COVID-19 have become evident. The overall amount of time in months that patients begin to stay aftercare is of concern. There are two researcher, each of whom follows a different set of 40 COVID-19 patients from the beginning of treatment through to death. Each researcher collects the following data (in months). Researcher 1: 3:4; 10; 15; 16; 17; 22; 44; 37; 16; 14; 24; 25; 15; 26; 27; 33; 30; 35; 44; 13; 21; 21; 10; 12; 8; 40; 32; 26; 27; 33; 34; 29; 17; 8; 24; 19; 47; 33; 34 Researcher 2: 3; 14; 15; 5; 16; 17; 28; 40; 30; 18; 14; 14; 26; 25; 21; 22; 31; 2; 35; 44; 23; 22; 22; 21; 16; 12; 18; 41; 22; 16; 27; 33; 34; 29; 13; 18; 24; 24; 42; 33; 29 A. if the second researcher performed is survey by choosing 40 patients whom he knew, what method of sampling would the researcher have employed? What concerns would you have regarding this data set, based on the method or data collection?